請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50059
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 潘敏雄 | |
dc.contributor.author | Yu-Hsuan Lin | en |
dc.contributor.author | 林宇軒 | zh_TW |
dc.date.accessioned | 2021-06-15T12:28:48Z | - |
dc.date.available | 2021-08-24 | |
dc.date.copyright | 2016-08-24 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-08 | |
dc.identifier.citation | 林口長庚醫院減重中心. (2016). 減重手術. https://www1.cgmh.org.tw/intr/intr2/c3210/bariatric/p2_service.asp (accessed June 10, 2016).
衛生福利部. (2006). 掌握「四少一多」、「1824」原則 打造健康身心好基礎. http://www.nhi.gov.tw/webdata/webdata.aspx?menu=6&menu_id=168&webdata_id=1455 (accessed June 5, 2016). 衛生福利部. (2014). 2014健康一世:BMI維持1824 揪團減重馬上行動. http://www.mohw.gov.tw/news/455443610 (accessed June 5, 2016). 衛生福利部. (2015). 103年國人死因統計結果. http://www.mohw.gov.tw/news/531349778 (accessed June 6, 2016). 衛生福利部. (2016). BMI測試. http://health99.hpa.gov.tw/OnlinkHealth/Onlink_BMI.aspx (accessed June 5, 2016). 衛生福利部食藥署. (2012). 每日飲食指南手冊. http://www.hpa.gov.tw/BHPNet/web/Books/manual_content25.aspx (accessed June 6, 2016). Adam, T., Opie, L. H., & Essop, M. F. (2010). AMPK activation represses the human gene promoter of the cardiac isoform of acetyl-CoA carboxylase: Role of nuclear respiratory factor-1. Biochem Biophys Res Commun, 398(3), 495-499. Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013). PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med, 19(5), 557-566. Ali, A. T., Hochfeld, W. E., Myburgh, R., & Pepper, M. S. (2013). Adipocyte and adipogenesis. Eur J Cell Biol, 92(6-7), 229-236. Amarnath Satheesh, M., & Pari, L. (2006). The antioxidant role of pterostilbene in streptozotocin-nicotinamide-induced type 2 diabetes mellitus in Wistar rats. J Pharm Pharmacol, 58(11), 1483-1490. Andrabi, S. A., Spina, M. G., Lorenz, P., Ebmeyer, U., Wolf, G., & Horn, T. F. (2004). Oxyresveratrol (trans-2,3',4,5'-tetrahydroxystilbene) is neuroprotective and inhibits the apoptotic cell death in transient cerebral ischemia. Brain Res, 1017(1-2), 98-107. Andrade, J. M., Paraiso, A. F., de Oliveira, M. V., Martins, A. M., Neto, J. F., Guimaraes, A. L., Santos, S. H. (2014). Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition, 30(7-8), 915-919. Ashraf, M. I., Shahzad, M., & Shabbir, A. (2015). Oxyresveratrol ameliorates allergic airway inflammation via attenuation of IL-4, IL-5, and IL-13 expression levels. Cytokine, 76(2), 375-381. Auwerx, J., Leroy, P., & Schoonjans, K. (1992). Lipoprotein lipase: recent contributions from molecular biology. Crit Rev Clin Lab Sci, 29(3-4), 243-268. Backhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Gordon, J. I. (2004). The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A, 101(44), 15718-15723. Backhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007). Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A, 104(3), 979-984. Bauche, I. B., El Mkadem, S. A., Pottier, A. M., Senou, M., Many, M. C., Rezsohazy, R., Brichard, S. M. (2007). Overexpression of adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation. Endocrinology, 148(4), 1539-1549. Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov, 5(6), 493-506. Begley, M., Hill, C., & Gahan, C. G. (2006). Bile salt hydrolase activity in probiotics. Appl Environ Microbiol, 72(3), 1729-1738. Belcheva, A., Irrazabal, T., & Martin, A. (2015). Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health? Bioessays, 37(4), 403-412. Berger, J., & Moller, D. E. (2002). The mechanisms of action of PPARs. Annu Rev Med, 53, 409-435. Blaszkiewicz, M., & Townsend, K. L. (2016). Adipose Tissue and Energy Expenditure: Central and Peripheral Neural Activation Pathways. Curr Obes Rep. Boini, K. M., Zhang, C., Xia, M., Poklis, J. L., & Li, P. L. (2010). Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther, 334(3), 839-846. Bonnefont, J. P., Djouadi, F., Prip-Buus, C., Gobin, S., Munnich, A., & Bastin, J. (2004). Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med, 25(5-6), 495-520. Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Lozupone, C. A., Turnbaugh, P. J., Knight, R. (2011). Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A, 108 Suppl 1, 4516-4522. Catalgol, B., Batirel, S., Taga, Y., & Ozer, N. K. (2012). Resveratrol: French paradox revisited. Front Pharmacol, 3, 141. Cawthorn, W. P., Scheller, E. L., Learman, B. S., Parlee, S. D., Simon, B. R., Mori, H., MacDougald, O. A. (2014). Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab, 20(2), 368-375. Chen, Z., Shen, X., Shen, F., Zhong, W., Wu, H., Liu, S., & Lai, J. (2013). TAK1 activates AMPK-dependent cell death pathway in hydrogen peroxide-treated cardiomyocytes, inhibited by heat shock protein-70. Mol Cell Biochem, 377(1), 35-44. Chirala, S. S., Jayakumar, A., Gu, Z. W., & Wakil, S. J. (2001). Human fatty acid synthase: role of interdomain in the formation of catalytically active synthase dimer. Proc Natl Acad Sci U S A, 98(6), 3104-3108. Choi, H. Y., Lee, J. H., Jegal, K. H., Cho, I. J., Kim, Y. W., & Kim, S. C. (2016). Oxyresveratrol abrogates oxidative stress by activating ERK-Nrf2 pathway in the liver. Chem Biol Interact, 245, 110-121. Choi, S., & Snider, A. J. (2015). Sphingolipids in High Fat Diet and Obesity-Related Diseases. Mediators Inflamm, 2015, 520618. Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011). Human fatty liver disease: old questions and new insights. Science, 332(6037), 1519-1523. Da Poian, A. T., El-Bacha, T., & Luz, M. R. M. P. (2010). Nutrient Utilization in Humans: Metabolism Pathways. Nature Education, 3(9), 11. Day, C. P., & James, O. F. (1998). Steatohepatitis: a tale of two 'hits'? Gastroenterology, 114(4), 842-845. DiBaise, J. K., Frank, D. N., & Mathur, R. (2012). Impact of the Gut Microbiota on the Development of Obesity: Current Concepts. Am J Gastroenterol Suppl, 1(1), 22-27. Diez, J. J., & Iglesias, P. (2010). The role of the novel adipocyte-derived protein adiponectin in human disease: an update. Mini Rev Med Chem, 10(9), 856-869. Dowman, J. K., Tomlinson, J., & Newsome, P. (2010). Pathogenesis of non-alcoholic fatty liver disease. Qjm, 103(2), 71-83. Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E., & Sul, H. S. (2007). Regulation of lipolysis in adipocytes. Annu Rev Nutr, 27, 79-101. Egan, J. J., Greenberg, A. S., Chang, M. K., Wek, S. A., Moos, M. C., Jr., & Londos, C. (1992). Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormone-sensitive lipase to the lipid storage droplet. Proc Natl Acad Sci U S A, 89(18), 8537-8541. Ellulu, M. S., Khaza'ai, H., Rahmat, A., Patimah, I., & Abed, Y. (2016). Obesity can predict and promote systemic inflammation in healthy adults. Int J Cardiol, 215, 318-324. Fernandez, M. L., & Webb, D. (2008). The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr, 27(1), 1-5. Ferre, P., & Foufelle, F. (2007). SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res, 68(2), 72-82. Fillmore, N., Mori, J., & Lopaschuk, G. D. (2014). Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol, 171(8), 2080-2090. Fischer-Posovszky, P., Kukulus, V., Tews, D., Unterkircher, T., Debatin, K. M., Fulda, S., & Wabitsch, M. (2010). Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr, 92(1), 5-15. Foster, D. W. (2012). Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J Clin Invest, 122(6), 1958-1959. Fredriksson, R., Hagglund, M., Olszewski, P. K., Stephansson, O., Jacobsson, J. A., Olszewska, A. M., Schioth, H. B. (2008). The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain. Endocrinology, 149(5), 2062-2071. Fremont, L. (2000). Biological effects of resveratrol. Life Sci, 66(8), 663-673. Friedman, H. I., & Nylund, B. (1980). Intestinal fat digestion, absorption, and transport. A review. Am J Clin Nutr, 33(5), 1108-1139. Gencer, B., Auer, R., de Rekeneire, N., Butler, J., Kalogeropoulos, A., Bauer, D. C., Rodondi, N. (2016). Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. Atherosclerosis, 245, 181-186. Giudetti, A. M., Stanca, E., Siculella, L., Gnoni, G. V., & Damiano, F. (2016). Nutritional and Hormonal Regulation of Citrate and Carnitine/Acylcarnitine Transporters: Two Mitochondrial Carriers Involved in Fatty Acid Metabolism. Int J Mol Sci, 17(6). Gomez-Zorita, S., Fernandez-Quintela, A., Lasa, A., Aguirre, L., Rimando, A. M., & Portillo, M. P. (2014). Pterostilbene, a dimethyl ether derivative of resveratrol, reduces fat accumulation in rats fed an obesogenic diet. J Agric Food Chem, 62(33), 8371-8378. Grabacka, M., & Reiss, K. (2008). Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation. PPAR Res, 2008, 930705. Griffin, M. J., Wong, R. H., Pandya, N., & Sul, H. S. (2007). Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter. J Biol Chem, 282(8), 5453-5467. Hannah, W. N., Jr., & Harrison, S. A. (2016). Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease. Clin Liver Dis, 20(2), 339-350. Hardie, D. G. (2013). AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer. Diabetes, 62(7), 2164-2172. Hawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D., & Hardie, D. G. (1996). Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem, 271(44), 27879-27887. Holowacz, S., Guigné, C., Chêne, G., Mouysset, S., Guilbot, A., Seyrig, C., & Dubourdeau, M. (2015). A multispecies Lactobacillus- and Bifidobacterium-containing probiotic mixture attenuates body weight gain and insulin resistance after a short-term challenge with a high-fat diet in C57/BL6J mice. PharmaNutrition, 3(3), 101-107. Houten, S. M., & Wanders, R. J. A. (2010). A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis, 33(5), 469-477. Hsu, C. L., Lin, Y. J., Ho, C. T., & Yen, G. C. (2012). Inhibitory effects of garcinol and pterostilbene on cell proliferation and adipogenesis in 3T3-L1 cells. Food Funct, 3(1), 49-57. Inoue, M., Ohtake, T., Motomura, W., Takahashi, N., Hosoki, Y., Miyoshi, S., Okumura, T. (2005). Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun, 336(1), 215-222. Jain, S. S., Ramanand, S. J., Ramanand, J. B., Akat, P. B., Patwardhan, M. H., & Joshi, S. R. (2011). Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab, 15(2), 99-104. Jeong, Y. S., Kim, D., Lee, Y. S., Kim, H. J., Han, J. Y., Im, S. S., Cha, J. Y. (2011). Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS One, 6(7), e22544. Jiang, S. J., Dong, H., Li, J. B., Xu, L. J., Zou, X., Wang, K. F., Yi, P. (2015). Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J Gastroenterol, 21(25), 7777-7785. Jogl, G., Hsiao, Y. S., & Tong, L. (2004). Structure and function of carnitine acyltransferases. Ann N Y Acad Sci, 1033, 17-29. Joseph, J. A., Fisher, D. R., Cheng, V., Rimando, A. M., & Shukitt-Hale, B. (2008). Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J Agric Food Chem, 56(22), 10544-10551. Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 444(7121), 840-846. Kanneganti, T. D., & Dixit, V. D. (2012). Immunological complications of obesity. Nat Immunol, 13(8), 707-712. Karmen, A., Whyte, M., & Goodman, D. S. (1963). Fatty acid esterification and chylomicron formation during fat absorption. 1. Triglycerides and cholesterol esters. J Lipid Res, 4, 312-321. Karmen, A., Wroblewski, F., & Ladue, J. S. (1955). Transaminase activity in human blood. J Clin Invest, 34(1), 126-131. Kenny, P. J. (2011). Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci, 12(11), 638-651. Kershaw, E. E., & Flier, J. S. (2004). Adipose tissue as an endocrine organ. J Clin Endocrinol Metab, 89(6), 2548-2556. Kwon, J. Y., Seo, S. G., Heo, Y. S., Yue, S., Cheng, J. X., Lee, K. W., & Kim, K. H. (2012). Piceatannol, natural polyphenolic stilbene, inhibits adipogenesis via modulation of mitotic clonal expansion and insulin receptor-dependent insulin signaling in early phase of differentiation. J Biol Chem, 287(14), 11566-11578. Kwon, J. Y., Seo, S. G., Yue, S., Cheng, J. X., Lee, K. W., & Kim, K. H. (2012). An inhibitory effect of resveratrol in the mitotic clonal expansion and insulin signaling pathway in the early phase of adipogenesis. Nutr Res, 32(8), 607-616. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Auwerx, J. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127(6), 1109-1122. Lai, C. S., Liao, S. N., Tsai, M. L., Kalyanam, N., Majeed, M., Majeed, A., Pan, M. H. (2015). Calebin-A inhibits adipogenesis and hepatic steatosis in high-fat diet-induced obesity via activation of AMPK signaling. Mol Nutr Food Res, 59(10), 1883-1895. Lee, H., Lee, Y. J., Choi, H., Ko, E. H., & Kim, J. W. (2009). Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion. J Biol Chem, 284(16), 10601-10609. Lee, J., Jung, E., Lee, J., Kim, S., Huh, S., Kim, Y., Park, D. (2009). Isorhamnetin represses adipogenesis in 3T3-L1 cells. Obesity (Silver Spring), 17(2), 226-232. Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006). Microbial ecology: human gut microbes associated with obesity. Nature, 444(7122), 1022-1023. Liang, H., & Ward, W. F. (2006). PGC-1α: a key regulator of energy metabolism. Advances in Physiology Education, 30(4), 145-151. Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G. J., Linton, E. F., & Vickers, K. C. (2000). The Role of Lipids and Lipoproteins in Atherosclerosis. In L. J. De Groot, P. Beck-Peccoz, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, C. Koch, R. McLachlan, M. New, R. Rebar, F. Singer, A. Vinik, & M. O. Weickert (Eds.), Endotext. South Dartmouth (MA): MDText.com, Inc. Liu, L., Li, J., Kundu, J. K., & Surh, Y. J. (2014). Piceatannol inhibits phorbol ester-induced expression of COX-2 and iNOS in HR-1 hairless mouse skin by blocking the activation of NF-kappaB and AP-1. Inflamm Res, 63(12), 1013-1021. Luo, Z., Zang, M., & Guo, W. (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 6(3), 457-470. McFadden, J. W., & Corl, B. A. (2009). Activation of AMP-activated protein kinase (AMPK) inhibits fatty acid synthesis in bovine mammary epithelial cells. Biochem Biophys Res Commun, 390(3), 388-393. Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Wahli, W. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev, 58(4), 726-741. Moore, J. B. (2010). Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc, 69(2), 211-220. Mozaffarian, D., Hao, T., Rimm, E. B., Willett, W. C., & Hu, F. B. (2011). Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med, 364(25), 2392-2404. Murias, M., Jager, W., Handler, N., Erker, T., Horvath, Z., Szekeres, T., Gille, L. (2005). Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol, 69(6), 903-912. Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation and metabolic disease. Nat Rev Immunol, 11(2), 85-97. Pan, H., Guo, J., & Su, Z. (2014). Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav, 130, 157-169. Park, B. G., Park, Y. S., Park, J. W., Shin, E., & Shin, W. S. (2016). Anti-obesity potential of enzymatic fragments of hyaluronan on high-fat diet-induced obesity in C57BL/6 mice. Biochem Biophys Res Commun, 473(1), 290-295. Park, J., Jeon, Y. D., Kim, H. L., Kim, D. S., Han, Y. H., Jung, Y., Um, J. Y. (2016). Veratri Nigri Rhizoma et Radix (Veratrum nigrum L.) and Its Constituent Jervine Prevent Adipogenesis via Activation of the LKB1-AMPKalpha-ACC Axis In Vivo and In Vitro. Evid Based Complement Alternat Med, 2016, 8674397. Pigeyre, M., Yazdi, F. T., Kaur, Y., & Meyre, D. (2016). Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci (Lond), 130(12), 943-986. Piotrowska, H., Kucinska, M., & Murias, M. (2012). Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res, 750(1), 60-82. Qiao, Y., Sun, J., Xia, S., Tang, X., Shi, Y., & Le, G. (2014). Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct, 5(6), 1241-1249. Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Wang, J. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490(7418), 55-60. Rahimian, R., Masih-Khan, E., Lo, M., van Breemen, C., McManus, B. M., & Dube, G. P. (2001). Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem, 224(1-2), 29-37. Ramji, D. P., & Foka, P. (2002). CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J, 365(Pt 3), 561-575. Ratziu, V., Goodman, Z., & Sanyal, A. (2015). Current efforts and trends in the treatment of NASH. J Hepatol, 62(1 Suppl), S65-75. Rayalam, S., Yang, J. Y., Ambati, S., Della-Fera, M. A., & Baile, C. A. (2008). Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res, 22(10), 1367-1371. Rehman Khan, A., & Awan, F. R. (2016). Leptin Resistance: A Possible Interface Between Obesity and Pulmonary-Related Disorders. Int J Endocrinol Metab, 14(1), e32586. Rimando, A. M., Nagmani, R., Feller, D. R., & Yokoyama, W. (2005). Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem, 53(9), 3403-3407. Rimando, A. M., & Suh, N. (2008). Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med, 74(13), 1635-1643. Rinella, M. E. (2015). Nonalcoholic fatty liver disease: a systematic review. Jama, 313(22), 2263-2273. Ruan, H., & Dong, L. Q. (2016). Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. Sanli, T., Linher-Melville, K., Tsakiridis, T., & Singh, G. (2012). Sestrin2 modulates AMPK subunit expression and its response to ionizing radiation in breast cancer cells. PLoS One, 7(2), e32035. Sanyal, A. J. (2002). AGA technical review on nonalcoholic fatty liver disease. Gastroenterology, 123(5), 1705-1725. Scheppach, W. (1994). Effects of short chain fatty acids on gut morphology and function. Gut, 35(1 Suppl), S35-38. Schreurs, M., Kuipers, F., & van der Leij, F. R. (2010). Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev, 11(5), 380-388. Schwiertz, A., Taras, D., Schafer, K., Beijer, S., Bos, N. A., Donus, C., & Hardt, P. D. (2010). Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring), 18(1), 190-195. Setoguchi, Y., Oritani, Y., Ito, R., Inagaki, H., Maruki-Uchida, H., Ichiyanagi, T., & Ito, T. (2014). Absorption and metabolism of piceatannol in rats. J Agric Food Chem, 62(12), 2541-2548. Sirerol, J. A., Rodriguez, M. L., Mena, S., Asensi, M. A., Estrela, J. M., & Ortega, A. L. (2016). Role of Natural Stilbenes in the Prevention of Cancer. Oxid Med Cell Longev, 2016, 3128951. Smith, S., Witkowski, A., & Joshi, A. K. (2003). Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res, 42(4), 289-317. Son, P. S., Park, S. A., Na, H. K., Jue, D. M., Kim, S., & Surh, Y. J. (2010). Piceatannol, a catechol-type polyphenol, inhibits phorbol ester-induced NF-{kappa}B activation and cyclooxygenase-2 expression in human breast epithelial cells: cysteine 179 of IKK{beta} as a potential target. Carcinogenesis, 31(8), 1442-1449. Stapleton, D., Mitchelhill, K. I., Gao, G., Widmer, J., Michell, B. J., Teh, T., Kemp, B. E. (1996). Mammalian AMP-activated protein kinase subfamily. J Biol Chem, 271(2), 611-614. Sun, L., Wang, Y., Song, Y., Cheng, X. R., Xia, S., Rahman, M. R., Le, G. (2015). Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice. Biochem Biophys Res Commun, 458(1), 86-91. Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Pittet, M. J. (2009). Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science, 325(5940), 612-616. Szkudelska, K., Nogowski, L., & Szkudelski, T. (2009). Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol, 113(1-2), 17-24. Tan, H. Y., Tse, I. M. Y., Li, E. T. S., & Wang, M. (2015). Inhibitory effects of oxyresveratrol and cyanomaclurin on adipogenesis of 3T3-L1 cells. Journal of Functional Foods, 15, 207-216. Tanaka, T., Yoshida, N., Kishimoto, T., & Akira, S. (1997). Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. Embo j, 16(24), 7432-7443. The Jackson Laboratory. (2016). C57BL/6J Detailed Description. https://www.jax.org/strain/000664 (accessed June 10, 2016). Tong, L. (2005). Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci, 62(16), 1784-1803. Toth, P. P. (2005). Cardiology patient page. The 'good cholesterol': high-density lipoprotein. Circulation, 111(5), e89-91. Tran, T. T., & Kahn, C. R. (2010). Transplantation of adipose tissue and stem cells: role in metabolism and disease. Nat Rev Endocrinol, 6(4), 195-213. Tsukumo, D. M., Carvalho, B. M., Carvalho Filho, M. A., & Saad, M. J. (2015). Translational research into gut microbiota: new horizons on obesity treatment: updated 2014. Arch Endocrinol Metab, 59(2), 154-160. Tyagi, S., Gupta, P., Saini, A. S., Kaushal, C., & Sharma, S. (2011). The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res, 2(4), 236-240. Uchida-Maruki, H., Inagaki, H., Ito, R., Kurita, I., Sai, M., & Ito, T. (2015). Piceatannol lowers the blood glucose level in diabetic mice. Biol Pharm Bull, 38(4), 629-633. Van Heek, M., Compton, D. S., France, C. F., Tedesco, R. P., Fawzi, A. B., Graziano, M. P., Davis, H. R., Jr. (1997). Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest, 99(3), 385-390. Vargas, R., Ortega, Y., Bozo, V., Andrade, M., Minuzzi, G., Cornejo, P., Videla, L. A. (2013). Thyroid hormone activates rat liver adenosine 5,-monophosphate-activated protein kinase: relation to CaMKKb, TAK1 and LKB1 expression and energy status. J Biol Regul Homeost Agents, 27(4), 989-999. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., & Walle, U. K. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos, 32(12), 1377-1382. Weaver, J. U. (2008). Classical endocrine diseases causing obesity. Front Horm Res, 36, 212-228. Weikel, K. A., Ruderman, N. B., & Cacicedo, J. M. (2016). Unraveling the actions of AMP-activated protein kinase in metabolic diseases: Systemic to molecular insights. Metabolism, 65(5), 634-645. WHO. (2015). Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed June 10, 2016). Winder, W. W., & Hardie, D. G. (1999). AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol, 277(1 Pt 1), E1-10. Wolever, T. M., Spadafora, P., & Eshuis, H. (1991). Interaction between colonic acetate and propionate in humans. Am J Clin Nutr, 53(3), 681-687. Wolter, F., Clausnitzer, A., Akoglu, B., & Stein, J. (2002). Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr, 132(2), 298-302. Yeh, W. C., Cao, Z., Classon, M., & McKnight, S. L. (1995). Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev, 9(2), 168-181. Yessoufou, A., & Wahli, W. (2010). Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly, 140, w13071. Zaidi, S. I., & Shirwany, T. A. (2015). Relationship of serum resistin with insulin resistance and obesity. J Ayub Med Coll Abbottabad, 27(3), 552-555. Zhang, T., Sawada, K., Yamamoto, N., & Ashida, H. (2013). 4-Hydroxyderricin and xanthoangelol from Ashitaba (Angelica keiskei) suppress differentiation of preadiopocytes to adipocytes via AMPK and MAPK pathways. Mol Nutr Food Res, 57(10), 1729-1740. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50059 | - |
dc.description.abstract | 肥胖已是全球性的健康問題,過多的脂肪堆積會導致許多疾病的發生,包括心血管疾病、非酒精性脂肪肝、癌症、第二型糖尿病、中風、骨關節炎等,如何預防肥胖或是減重已成為近年來科學家研究的重要議題之一。白皮杉醇 (Piceatannol) 是白藜蘆醇 (Resveratrol) 的類似物,已有多篇研究指出其生理功效,包含抗癌、抗發炎及降低血糖等。在細胞實驗中,白皮杉醇能有效減少3T3-L1細胞中的脂肪堆積,並抑制細胞擴增期 (Mitotic clonal expansion, MCE),但目前白皮杉醇在動物體內的抗肥胖效果還未被討論及研究,因此本實驗目的為評估白皮杉醇在動物模式中抗肥胖、脂肪肝及其調節機制之探討。本實驗中,將40隻五週齡雄性C57BL/6小鼠分成5組,分別是正常飲食 (n=8)、高脂飲食 (45% energy from fat, n=8)、高脂飲食混入0.1% Resveratrol (n=8)、高脂飲食混入0.1% Piceatannol (n=8) 和高脂飲食混入0.25% Piceatannol (n=8),自由攝食飼養18周後犧牲。結果顯示0.1% 和0.25% piceatannol組能顯著的降低小鼠的體重並呈現劑量效應,且不影響攝食量。血液中總膽固醇、血糖及LDL/HDL ratio也有顯著性的降低。在脂肪組織方面,0.1% 和0.25% Piceatannol組能顯著降低性腺脂肪和腹膜後脂肪重量,性腺脂肪切片顯示其脂肪細胞大小也有顯著性的下降。飼料添加Piceatannol組和高脂飲食組相比能顯著降低肝臟和脾臟重量,由肝臟切片也可看出脂肪空泡的數量和大小減少。Piceatannol透過增加pAMPK的表現量降低脂肪細胞分化轉錄因子C/EBPα和PPARγ,並影響pACC和FAS的表現量,減少脂肪酸的形成,進而減少三酸甘油酯的合成。綜合上述結果,Piceatannol在小鼠模式中能改善高脂飼料誘導之肥胖,減少體脂肪及脂肪肝,具有開發成不易形成體脂肪之保健食品的潛力。 | zh_TW |
dc.description.abstract | Obesity is a global health concern. Excess storage of lipids in adipose tissue is associated with cardiovascular disease, fatty liver, cancer, type 2 diabetes, stroke and osteoarthritis. Piceatannol, an analogue of resveratrol, was found to have anti-cancer, anti-inflammatory and hypoglycemic effects. Previous studies indicated that piceatannol significantly reduced lipid accumulation and inhibited mitotic clonal expansion phase in 3T3-L1 cell model. In this study we investigated the anti-obesity effect of piceatannol in vivo. Five-week-old Mice were fed ad libitum with normal diet (n=8), high-fat diet (45% energy from fat, n=8), high-fat diet with 0.1% resveratrol (n=8), high-fat diet with 0.1% piceatannol (n=8) and high-fat diet with 0.25% piceatannol (n=8) for 18 weeks. The results showed that 0.1% piceatannol and 0.25% piceatannol significantly reduced mice body weight in a dose-dependent manner without affecting their food intake. Serum total cholesterol levels, LDL/HDL ratio, and blood glucose were significantly lowered for both piceatannol-treated groups. As for adipose tissue, piceatannol significantly decreased the weight of perigonadal and retroperitoneal fat. The perigonadal adipose tissue histology showed a significant cell size reduction in piceatannol-treated groups. The weight of liver and spleen were significantly reduced compared with high-fat diet group. From hepatic histology, a decrease in lipid accumulation in both size and number were observed. Piceatannol showed a higher pAMPK expression and decreased expression of adipogenic transcriptional factors, C/EBPα and PPARγ. It also altered the expression of pACC and FAS, hence reduced the synthesis of fatty acid and triglyceride. Collectively, these results suggested that piceatannol could ameliorate high-fat-diet induced obesity, reduce adipose tissue weight and hepatic steatosis. It has potential to be further developed into functional food or medicine. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:28:48Z (GMT). No. of bitstreams: 1 ntu-105-R03641038-1.pdf: 6313207 bytes, checksum: 4120047686c3b31d970e7469a9b62c2e (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 謝誌 I
中文摘要 II Abstract III 目錄 IV 附圖目錄 VII 附表目錄 IX 圖目錄 X 表目錄 XI 縮寫表 XII 第一章、緒論 1 第二章、文獻回顧 2 第一節、肥胖 (Obesity) 2 (一) 簡介 2 (二) 肥胖的判定 2 (三) 造成肥胖的原因 3 (四) 肥胖導致的疾病 4 (五) 預防及治療 5 第二節、脂肪組織 (Adipose tissue) 7 (一) 簡介 7 (二) 脂肪分泌之荷爾蒙 (Adipose-derived hormones) 8 (三) 脂質生合成作用 (Lipogenesis) 10 (四) 脂解作用及beta氧化作用 (Lipolysis and beta-oxidation) 12 第三節、AMP-activated protein kinase pathway (AMPK pathway) 16 (一) Adenosine monophosphate-activated protein kinase (AMPK) 16 (二) Peroxisome proliferator-activated receptors (PPARs) 19 (三) CCAAT/enhancer-binding proteins (C/EBPs) 23 (四) Acetyl-CoA carboxylase (ACC) 24 (五) Fatty acid synthase (FAS) 25 (六) Carnitine palmitoyl transferase I (CPT-1) 26 第四節、非酒精性脂肪肝 (Non-alcoholic fatty liver disease, NAFLD) 27 (一) 簡介 27 (二) 致病機轉 28 (三) 預防及治療 30 第五節、腸道菌與肥胖 31 第六節、Stilbene化合物在細胞及動物實驗中的抗肥胖效果 33 (一) 白藜蘆醇 (Resveratrol) 33 (二) 白皮杉醇 (Piceatannol) 34 (三) 氧化白藜蘆醇 (Oxyresveratrol) 35 (四) 紫檀芪 (Pterostilbene) 36 第三章、實驗目的與架構 38 第一節、研究動機與目的 38 第二節、實驗架構 39 第四章、材料與方法 40 第一節、實驗設備 40 第二節、藥品試劑 41 第三節、動物飼養 44 (一) 動物品種 44 (二) 飼料配製 45 (三) 動物犧牲 46 第四節、分析方法 47 (一) 組織均質 47 (二) 蛋白質定量 48 (三) Western blot 49 (四) 血液生化數值分析 51 (五) 組織切片染色 52 (六) Next Generation Sequencing (NGS) 53 (七) 統計分析 54 第五章、結果與討論 55 (一) Piceatannol對高脂飲食C57BL/6小鼠體重之影響 55 (二) Piceatannol對高脂飲食C57BL/6小鼠攝食量之影響 56 (三) Piceatannol對高脂飲食C57BL/6小鼠脂肪重量之影響 57 (四) Piceatannol對高脂飲食C57BL/6小鼠脂肪細胞大小之影響 58 (五) Piceatannol對高脂飲食C57BL/6小鼠脂肪合成蛋白之影響 59 (六) Piceatannol對高脂飲食C57BL/6小鼠脂肪氧化蛋白之影響 60 (七) Piceatannol對高脂飲食C57BL/6小鼠器官重量之影響 61 (八) Piceatannol對高脂飲食C57BL/6小鼠肝臟脂肪之影響 61 (九) Piceatannol對高脂飲食C57BL/6小鼠肝臟脂肪合成蛋白之影響 62 (十) Piceatannol對高脂飲食C57BL/6小鼠血液生化數值之影響 63 (十一) Piceatannol對高脂飲食C57BL/6小鼠腸道菌群之影響 64 (十二) Piceatannol和Resveratrol在抗肥胖功效的比較及探討 67 第六章、結論 69 第七章、圖表 70 第八章、參考文獻 89 | |
dc.language.iso | zh-TW | |
dc.title | 白皮杉醇抑制小鼠肥胖的功效及相關分子機制的探討 | zh_TW |
dc.title | Piceatannol exerts anti-obesity effect involving modulation of adipogenic proteins in C57BL/6 mice | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳宏彰 | |
dc.contributor.oralexamcommittee | 何其儻,何元順,李銘仁 | |
dc.subject.keyword | 肥胖,白皮杉醇 (Piceatannol),高脂飲食,C57BL/6,AMPK, | zh_TW |
dc.subject.keyword | Obesity,Piceatannol,High-fat diet,C57BL/6,AMPK, | en |
dc.relation.page | 101 | |
dc.identifier.doi | 10.6342/NTU201602080 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-08 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 食品科技研究所 | zh_TW |
顯示於系所單位: | 食品科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 6.17 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。